Adagene Inc

Adagene insider Gu Chunfang’s latest holdings reveal strong management confidence and strategic alignment with its fast‑track antibody pipeline, signaling potential upside for investors.

Adagene insider activity shows senior execs hold long‑term positions tied to milestone‑based options, balancing dilution risk while aligning leadership incentives with the company’s clinical and commercial goals.